Biogen Inc Closed Now

Introduction
Biogen Inc. is an American multinational biotechnology company founded in 1978, and one of the world’s pioneers in neuroscience and neurological therapies. The company focuses on developing innovative treatments for neurological and neurodegenerative diseases, including multiple sclerosis (MS), Alzheimer’s disease, spinal muscular atrophy (SMA), Parkinson’s disease, and ALS (amyotrophic lateral sclerosis). Biogen has made groundbreaking contributions to biotechnology, particularly in biologics and therapies targeting the central nervous system (CNS).

Mission and Vision

• Mission: To pioneer science and deliver life-changing medicines for people with serious neurological and neurodegenerative diseases.

• Vision: To transform neuroscience into new hope for patients worldwide.

Products and Services

• Multiple Sclerosis (MS): Tecfidera, Avonex, Tysabri, and Vumerity.

• Spinal Muscular Atrophy (SMA): Spinraza (developed with Ionis Pharmaceuticals).

• Alzheimer’s Disease: Aduhelm and Leqembi (co-developed with Eisai).

• Biosimilars: A portfolio of biosimilar medicines for autoimmune and inflammatory diseases.

• Pipeline: Investigational drugs in Parkinson’s, ALS, depression, and ophthalmology.

Growth and Innovation
Biogen is at the forefront of neuroscience innovation, having developed the first FDA-approved treatment for SMA and pioneering therapies for MS. Its controversial but groundbreaking approval of Aduhelm, the first Alzheimer’s therapy targeting amyloid plaques, reflects Biogen’s ambition in tackling some of the most difficult diseases. The company also invests in gene therapy, antisense oligonucleotides, and digital biomarkers to advance precision medicine.